Lessee, Operating Lease, Liability, Undiscounted Excess Amount of Vitro Biopharma, Inc. from 31 Jan 2023 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
Summary
Vitro Biopharma, Inc. quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount in USD history and change rate from 31 Jan 2023 to 31 Oct 2025.
  • Vitro Biopharma, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount for the quarter ending 31 Oct 2025 was $71,312, a 71% decline year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Quarterly (USD)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, YoY Quarterly Change (%)

Vitro Biopharma, Inc. Quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $71,312 -$178,492 -71% 31 Oct 2025 10-K 13 Feb 2026 2025 FY
Q2 2025 $217,747 -$41,102 -16% 31 Jul 2025 10-Q 12 Sep 2025 2025 Q3
Q1 2025 $229,251 -$37,758 -14% 30 Apr 2025 10-Q 20 Jun 2025 2025 Q2
Q4 2024 $239,929 -$34,363 -13% 31 Jan 2025 10-Q 20 Mar 2025 2025 Q1
Q3 2024 $249,804 -$30,894 -11% 31 Oct 2024 10-K 28 Jan 2025 2024 FY
Q2 2024 $258,849 -$25,357 -8.9% 31 Jul 2024 10-Q 16 Sep 2024 2024 Q3
Q1 2024 $267,009 +$33,281 +14% 30 Apr 2024 10-Q 31 May 2024 2024 Q2
Q4 2023 $274,292 +$36,303 +15% 31 Jan 2024 10-Q 14 Mar 2024 2024 Q1
Q3 2023 $280,698 31 Oct 2023 10-K 29 Jan 2024 2023 FY
Q2 2023 $284,206 31 Jul 2023 10-Q 28 Aug 2023 2023 Q3
Q1 2023 $233,728 30 Apr 2023 10-Q 13 Jun 2023 2023 Q2
Q4 2022 $237,989 31 Jan 2023 10-Q 14 Mar 2023 2023 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.